Pressat published an article about Codivir, a new drug by Code Pharma against COVID-19: “Despite the various vaccines, new variants are still being discovered. However, beyond vaccines, there is a great drive towards developing antiviral medication like Codivir, which medical experts consider as one of the most advanced drugs in their capabilities”.
Zyon Ayni, Code Pharma’s Founder and CEO, said: “We are negotiating with manufacturers around the world. With the successful completion of Phase II, we anticipate that most countries in the world will approve the medication under emergency approval. We are preparing for a broad global response in a short time; a move to ensure the company captures the world’s largest market share in a brief period”.